Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minima...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
13 May 2015
|
| In: |
Expert opinion on biological therapy
Year: 2015, Volume: 15, Issue: 8, Pages: 1093-1099 |
| ISSN: | 1744-7682 |
| DOI: | 10.1517/14712598.2015.1041373 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1517/14712598.2015.1041373 Verlag, Volltext: https://doi.org/10.1517/14712598.2015.1041373 
|
| Author Notes: | Julia Stieglmaier, Jonathan Benjamin and Dirk Nagorsen |
| Summary: | Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal binding domains of monoclonal antibodies for tumor-associated surface antigens and for the T-cell receptor-associated molecule CD3. Concurrent engagement of the target cell antigen and CD3 leads to activation of polyclonal cytotoxic T-cells, resulting in target cell lysis. Blinatumomab, a BiTE targeting CD19, is being investigated in a broad range of B-cell malignancies and has recently been approved in the USA by the US FDA for Philadelphia chromosome-negative relapsed/refractory B-acute lymphoblastic leukemia under the trade name BLINCYTO™. The BiTE platform is one of the clinically most advanced T-cell immunotherapy options. |
|---|---|
| Item Description: | Gesehen am 07.01.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1744-7682 |
| DOI: | 10.1517/14712598.2015.1041373 |